abstract |
Use of hematopoietic stem cells (HSC), hematopoietic progenitor cells (HPC), myeloid/monocyte committed progenitor cells, macrophages or monocytes comprising a vector for the prevention or treatment of cancer in a patient, wherein the vector comprises At least one mir-130a and/or mir-126 target sequence operably linked to a nucleotide sequence encoding interferon alpha (IFNα), wherein the HSC, the HPC, the myeloid/monocyte committed Progenitor cells, the macrophages or the monocytes are used in combination with immune checkpoint inhibitors and/or tumor associated antigen (TAA) specific T cells. |